PTPN11 and neoplasm: SHP2 inhibitors that were initially developed to target oncogenic signaling in tumors are now known to confer additional immunomodulatory effects, influencing macrophage subsets, depleting pro-tumorigenic populations, and enhancing tumor sensitivity to additional immunotherapies (Lorenz, 2009; Xiao et al, 2018; Christofides et al, 2023).